Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30865056 | 1.00 | PKM (0.42) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL30865055 | 1.00 | PKM (0.42) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL30659789 | 0.87 | TDP1 (0.43) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL31590755 | 0.87 | PKM (0.45) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL8643924 | 0.87 | PKM (0.45) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL16322035 | 0.86 | HTT (0.44) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL17051176 | 0.84 | PKM (0.40) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL25358878 | 0.82 | PKM (0.39) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL28787371 | 0.82 | PKM (0.39) | PKMTDP1KDM4EL3MBTL1POLB | |
| SCHEMBL1579201 | 0.81 | KDM4E (0.45) | PKMTDP1KDM4EL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026017463-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED 1,2-DIFLUORO-4-METHOXY-3-NITROBENZENE AND 1,2,3-TRIFLUORO-5-METHOXY-4-NITROBENZENE | BASF SE (DE) | 2026-01-22 | — | — | WO | disclosed |
| WO-2026017463-A1 | PROCESS FOR THE PREPARATION OF HALOGENATED 1,2-DIFLUORO-4-METHOXY-3-NITROBENZENE AND 1,2,3-TRIFLUORO-5-METHOXY-4-NITROBENZENE | BASF SE (DE) | 2026-01-22 | — | — | WO | disclosed |
| CN-117913367-A | Preparation method of composite organic solvent, electrolyte and lithium-sulfur battery | 东方电气集团科学技术研究院有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2021060281-A1 | PROSTAGLANDIN E2 RECEPTOR EP2/EP4 DUAL ANTAGONIST | ＡＧＣ株式会社 | 2021-04-01 | — | — | WO | disclosed |
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | ALLOMEK THERAPEUTICS, LLC | 2015-09-10 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034861-B2 | MEK inhibitors useful in the treatment of diseases | ALLOMEK THERAPEUTICS LLC (US) | 2015-05-19 | — | — | US | disclosed |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2011047055-A2 | NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES | ALLOSTEM THERAPEUTICS LLC (US) | 2011-04-21 | — | — | WO | disclosed |
| CN-101671262-A | Method for producing ortho-trifluoro-methoxyaniline | FUXIN DAYI CHEMICAL INST CO LT | 2010-03-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250762-A1 | NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS | MYLK2, MAPK1, MAP3K1 | PKM 265/4885TDP1 1271/4885KDM4E 953/4885 |
| US-20120208859-A1 | NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES | NRAS, BRAF, MAP3K20 | PKM 397/4885TDP1 1756/4885KDM4E 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.